Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
The approval adds a new indication for GLP-1 drugs and gives Novo an advantage over Lilly’s rival diabetes drug Mounjaro, ...
23h
Ozempic’s expanded approval in the U.S. could transform how doctors treat patients with the condition, which involves a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback